biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
MEREO BIOPHARMA GROUP projects
22 ClinicalTrials.gov programs sponsored by MEREO BIOPHARMA GROUP.
MEREO BIOPHARMA GROUP has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Active treatment with a high dose of BGS649
Mereo BioPharma Group plc
Endometriosis
1 trial -
Alvelestat
Mereo BioPharma Group plc
Covid19
1 trial -
Alvelestat (MPH966)
Mereo BioPharma Group plc
Alpha-1 Antitrypsin Deficiency (AATD)
1 trial -
BCT197
Mereo BioPharma Group plc
Pulmonary Disease, Chronic Obstructive
1 trial -
BCT197
Mereo BioPharma Group plc
Chronic Obstructive Pulmonary Disease
1 trial -
BCT197 Part A
Mereo BioPharma Group plc
Acute Kidney Injury
1 trial -
BGS649
Mereo BioPharma Group plc
Hypogonadotropic Hypogonadism
2 trials -
BGS649
Mereo BioPharma Group plc
Pelvic Pain Associated With Refractory Endometriosis
1 trial -
BPS804
Mereo BioPharma Group plc
Osteogenesis Imperfecta
1 trial -
BPS804
Mereo BioPharma Group plc
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
1 trial -
BPS804
Mereo BioPharma Group plc
Hypophosphatasia
1 trial -
BPS804 20mg/Kg
Mereo BioPharma Group plc
Osteopenia
1 trial -
Demcizumab
Mereo BioPharma Group plc
Pancreatic Cancer
2 trials -
Etigilimab
Mereo BioPharma Group plc
Solid Tumor, Adult
1 trial -
Investigational new drug company code: BGS649
Mereo BioPharma Group plc
Obese Hypogonadotropic Hypogonadism
1 trial -
MPH966
Mereo BioPharma Group plc
Hematologic Malignancy
1 trial -
Nivolumab
Mereo BioPharma Group plc
Ovarian Cancer
1 trial -
OMP-59R5
Mereo BioPharma Group plc
Stage IV Pancreatic Cancer
1 trial -
OMP-59R5
Mereo BioPharma Group plc
Stage IV Small Cell Lung Cancer
1 trial -
Pemetrexed
Mereo BioPharma Group plc
Nonsquamous Nonsmall Cell Neoplasm of Lung
1 trial -
Placebo Oral Tablet
Mereo BioPharma Group plc
Alpha 1-Antitrypsin Deficiency
1 trial -
setrusumab
Mereo BioPharma Group plc
Osteogenesis Imperfecta, Type I
1 trial
Frequently asked questions
How many clinical projects does MEREO BIOPHARMA GROUP have?
22 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.